Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

AMGN.NASDAQ

Amgen

Healthcare | Drug Manufacturers - General

Biotechnology pioneer discovering, developing, manufacturing, and delivering human therapeutics for serious illnesses.

Flagship Insight

How Sovereign Manufacturing Moats Shield This Leveraged Biotech From Patent Cliffs

There is high consensus that this biopharma giant faces a critical transition as legacy patent cliffs collide with its emerging metabolic pipeline. While leverage remains elevated, sovereign domestic manufacturing infrastructure and robust free cash flow provide a powerful structural shield against geopolitical supply disruptions and regulatory pricing pressures.

Forecast TimelineUpdated On Jul 02 2026

Amgen (AMGN) Stock Forecast and AI Rating

Recommendation

Small Buy

Open a small position; wait before adding more.

2027

1-Year

BUY

$413

+10.5%

+12.4% IF INCL. DIVS

2029

3-Year

N/A

$485

+32%

2031

5-Year

BUY

$572

+53%

+74% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The asset is navigating a complex multi-year transition where legacy patent cliffs on high-margin blockbusters are offset by rare-disease cash flows and the commercialization of a novel monthly-dosing metabolic pipeline. While high leverage from recent acquisitions presents near-term balance sheet friction, the firm's sovereign domestic manufacturing footprint provides a powerful structural moat under emerging geopolitical and regulatory frameworks, positioning it as an all-weather defensive compounder.

Key insights

Differentiated monthly dosing architecture in the metabolic pipeline addresses patient compliance fatigue, capturing significant market share from weekly incumbents.
Sovereign domestic biomanufacturing capacity insulates operations from geopolitical supply chain decoupling and legislative procurement restrictions under the BIOSECURE Act.
High balance sheet leverage restricts near-term capital allocation flexibility, temporarily sidelining aggressive share repurchases and bolt-on acquisitions.
Impending loss of exclusivity for legacy bone-health blockbusters creates a predictable revenue drag that requires flawless pipeline execution.
Robust free cash flow generation provides a strong valuation floor and enables systematic deleveraging in a restrictive rate environment.
Regulatory pricing interventions and populist policy frameworks cap net pricing power, shifting the growth burden to volume expansion.
Valuation multiples are currently rich, demanding flawless clinical execution to justify the embedded growth premium.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Amgen quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Amgen.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$366.67	$380.07	$389.12	$736.09
Quarter 2+6M	Jan 02, 2027	$355.67	$389.04	$404.64	$724.14
Quarter 3+9M	Apr 02, 2027	$362.56	$397.15	$420.83	$713.57
Quarter 4+1Y	Jul 02, 2027	$351.40	$402.59	$429.25	$723.38
Quarter 5+15M	Oct 02, 2027	$337.34	$413.41	$455.00	$716.61
Quarter 6+18M	Jan 02, 2028	$320.48	$423.86	$477.75	$738.34
Quarter 7+21M	Apr 02, 2028	$326.89	$432.44	$473.42	$746.91
Quarter 8+2Y	Jul 02, 2028	$307.27	$434.18	$487.63	$771.93
Quarter 9+27M	Oct 02, 2028	$298.05	$442.64	$502.25	$782.73
Quarter 10+30M	Jan 02, 2029	$307.00	$457.67	$526.61	$807.31
Quarter 11+33M	Apr 02, 2029	$300.86	$461.48	$542.08	$822.72
Quarter 12+3Y	Jul 02, 2029	$288.82	$474.25	$558.35	$846.10
Quarter 13+39M	Oct 02, 2029	$274.38	$484.55	$569.51	$852.53
Quarter 14+42M	Jan 02, 2030	$263.41	$499.86	$597.99	$882.91
Quarter 15+45M	Apr 02, 2030	$273.94	$512.45	$620.61	$900.46
Quarter 16+4Y	Jul 02, 2030	$279.42	$523.30	$651.64	$922.67
Quarter 17+51M	Oct 02, 2030	$282.21	$532.30	$671.19	$935.91
Quarter 18+54M	Jan 02, 2031	$290.68	$549.28	$684.61	$952.30
Quarter 19+57M	Apr 02, 2031	$296.49	$557.80	$690.72	$976.28
Quarter 20+5Y	Jul 02, 2031	$299.46	$571.75	$718.35	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's systematic underappreciation of the company's secure domestic biomanufacturing infrastructure and the structural advantages of its metabolic dosing architecture. While the crowd obsesses over weekly prescription volumes and near-term patent expirations, it overlooks how the BIOSECURE Act will choke competitors reliant on foreign contract manufacturers. The company's massive, fully-owned domestic facilities act as a powerful geopolitical moat, ensuring unconstrained supply. Furthermore, the market misprices the compliance advantage of monthly or quarterly dosing over weekly regimens, which directly addresses patient fatigue. Finally, the crowd underestimates the rapid deleveraging enabled by the highly resilient rare-disease cash flows, which will soon unlock massive share buybacks.

Advisor Disagreement

The primary disagreement across the reports centers on the valuation multiple and the speed of metabolic market disruption. Some analyses argue that the current valuation is excessively rich, pricing in flawless execution and ignoring the threat of rapid commoditization from next-generation oral competitors. Conversely, other perspectives suggest the market is severely underpricing the company's secure domestic manufacturing moat and the long-term cash-compounding power of its rare-disease portfolio, which could drive substantial multiple expansion.

Financial Reviews by iPulse AI

Earnings and financials

The company is showing strong top-line revenue growth, driven by its newly acquired rare-disease treatments and established cardiovascular drugs. However, actual net income and free cash flow have faced some pressure due to the high costs of integrating these new businesses and paying off debt. Analysts agree that the company's ability to generate cash remains highly resilient, providing a safe cushion during economic uncertainty. However, there is a clear disagreement about the future path: some believe that upcoming patent expirations on older, high-margin drugs will cause a temporary drop in earnings, while others argue that the rapid scaling of new treatments will easily bridge the gap. Overall, the company's financial engine is strong, but its future growth depends heavily on the successful launch of its new pipeline.

Profitability and margins

The company maintains exceptionally high gross margins, reflecting the strong pricing power of its specialized biologic drugs. However, operating and net margins have been squeezed recently by high research costs and acquisition-related expenses. Analysts agree that margins will face continued pressure as older, highly profitable blockbusters lose patent protection and face cheap generic competition. The main point of disagreement is how quickly margins will recover. Optimists believe that the high-margin rare-disease portfolio and automated manufacturing will quickly restore profitability, while cautious observers warn that launching a mass-market weight-loss drug will require massive marketing spend that will keep margins depressed for longer.

Balance sheet and leverage

The company's balance sheet is currently its biggest weak spot, carrying a very high level of debt from a massive recent acquisition. While the company has sufficient cash and short-term assets to meet its immediate obligations, its high debt load limits its financial flexibility. Analysts agree that the company is actively using its strong cash flow to pay down this debt rapidly, which is steadily improving its financial health. However, there is disagreement on the level of risk this debt poses in a high-interest-rate environment. Some warn that refinancing this debt will be expensive and will eat into profits, while others believe the highly stable, non-discretionary demand for the company's life-saving medicines makes the debt easily manageable.

Capex and investment intensity

The company is spending heavily on research and development, particularly to fund expensive late-stage clinical trials for its weight-loss drug. While this high spending pressures short-term cash flow, analysts agree it is a necessary investment to stay competitive in the fast-growing metabolic market. Physical capital spending on factories is relatively low and disciplined, as the company has already built massive, state-of-the-art manufacturing facilities in the US. Opinions differ on the efficiency of this spending: some view the rising research budget as a risky gamble on a single drug, while others see it as a vital step toward building a high-tech, automated drug discovery platform. For retail investors, this heavy investment means the company is prioritizing long-term growth over immediate cash returns.